Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
Phase 2 Recruiting
165 enrolled
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Phase 2 Recruiting
2,900 enrolled
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Phase 2 Recruiting
285 enrolled
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
Phase 2 Recruiting
80 enrolled
Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery
Phase 2 Recruiting
148 enrolled
Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro
Phase 2 Recruiting
20 enrolled
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
Phase 2 Recruiting
114 enrolled
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
Phase 2 Recruiting
332 enrolled
Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy
Phase 2 Recruiting
20 enrolled
Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy
Phase 2 Recruiting
86 enrolled
panSOHO
Phase 2 Recruiting
111 enrolled
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
Phase 2 Recruiting
24 enrolled
Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib
Phase 2 Recruiting
48 enrolled
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Phase 2 Recruiting
200 enrolled
Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)
Phase 2 Recruiting
37 enrolled
IPROC
Phase 2 Recruiting
60 enrolled
N-Plus
Phase 2 Recruiting
640 enrolled
DENALI
Phase 2 Recruiting
170 enrolled
PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Phase 2 Recruiting
43 enrolled
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Phase 2 Recruiting
492 enrolled
A Study of Isoquercetin in People With Ovarian Cancer
Phase 2 Recruiting
90 enrolled
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Phase 2 Recruiting
740 enrolled
Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer
Phase 2 Recruiting
33 enrolled
Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery
Phase 2 Recruiting
86 enrolled
Autophagy Maintenance (AUTOMAIN)
Phase 2 Recruiting
38 enrolled
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Phase 2 Recruiting
27 enrolled
Phase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian Cancer
Phase 2 Recruiting
20 enrolled
A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
Phase 2 Recruiting
100 enrolled
Efficacy and Safety of Distamab Vedotin Combined With Carboplatin for Advanced Ovarian Cancer in the First Line Treatment
Phase 2 Recruiting
20 enrolled
A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors
Phase 2 Recruiting
130 enrolled
ANALLISA
Phase 2 Recruiting
30 enrolled
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
Phase 2 Recruiting
320 enrolled
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
Phase 2 Recruiting
32 enrolled
Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer
Phase 2 Recruiting
18 enrolled
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Phase 2 Recruiting
270 enrolled
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
Phase 2 Recruiting
30 enrolled
A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer
Phase 2 Recruiting
40 enrolled
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
Phase 2 Recruiting
30 enrolled
HERO
Phase 2 Recruiting
88 enrolled
KOV-02S
Phase 2 Recruiting
80 enrolled
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Phase 2 Recruiting
70 enrolled
Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer
Phase 2 Recruiting
31 enrolled
Chemotherapy Combined With Propranolol Hydrochloride as Neoadjuvant Therapy for Advanced High-grade Serous Ovarian Cancer
Phase 2 Recruiting
40 enrolled
Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
Phase 2 Recruiting
32 enrolled
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Phase 2 Recruiting
582 enrolled
OC-POP-PT
Phase 2 Recruiting
60 enrolled
DAB
Phase 2 Recruiting
39 enrolled
PRESELECT-0
Phase 2 Recruiting
18 enrolled
Preselect-1
Phase 2 Recruiting
126 enrolled
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
Phase 2 Recruiting
51 enrolled